Trenchant Provides Update on Corporate Developments of and Investment in GNQ Insilico Inc.
Trenchant Provides Update on Corporate Developments of and Investment in GNQ Insilico Inc.
Vancouver, British Columbia--(Newsfile Corp. - March 6, 2024) - Trenchant Capital Corp. (CSE: TCC) (the "Company") announces that GNQ Insilico Inc. ("GNQ") has reported that it has commenced the development of an in silico clinical trial platform with a technology-based Fortune 100 company. On November 6, 2023, GNQ signed a Memorandum of Understanding with the Fortune 100 company to develop and commercialize an artificial intelligence (AI) driven drug development platform that integrates GNQ's genomics and epigenetic analytics, generated over 10 years through data from 15,000 case studies. The full corporate update from GNQ can be accessed here: .
不列顛哥倫比亞省溫哥華--(Newsfile Corp.,2024 年 3 月 6 日)——Trenchant Capital Corp.(CSE:TCC)(”公司“) 宣佈 GNQ Insilico Inc. (”GNQ“)報告說,它已開始與一家以技術爲基礎的財富100強公司共同開發計算機臨床試驗平台。2023年11月6日,GNQ與財富100強公司簽署了一份諒解備忘錄,以開發和商業化人工智能(AI)驅動的藥物開發平台,該平台整合了GNQ的基因組學和表觀遺傳學分析,該平台是通過來自15,000個案例研究的數據在10年內生成的。可以在此處訪問GNQ的完整公司更新:.
"Our collaboration with a Fortune 100 technology company and its leadership in AI and quantum computing will empower GNQ Insilico to further advance its genomics-driven generative AI in silico clinical trials platform. Given the current challenges facing life sciences companies in cost effective and timely drug development, we believe that our platform can be a game changer in helping these companies more rapidly bring their drugs to market," states Rehan Huda, Founder and Chief Executive Officer of GNQ.
“我們與財富100強科技公司的合作及其在人工智能和量子計算領域的領導地位將使GNQ Insilico能夠進一步推進其基因組學驅動的生成式人工智能計算機臨床試驗平台。鑑於生命科學公司當前在具有成本效益和及時的藥物開發方面面臨的挑戰,我們相信我們的平台可以改變遊戲規則,幫助這些公司更快地將藥物推向市場。” GNQ創始人兼首席執行官雷漢·胡達說。
GNQ was formed in August 2023 by My Next Health Inc. ("MNH"), a Delaware incorporated healthcare company with a vision to improve the global healthcare sector by deploying a genomics-based AI and quantum platform for clinical trials and point of care solutions. MNH's platform uses proprietary insights on how systems of genes interact with each other as well as with epigenetic factors to drive key metabolic pathways. These insights are based on more than 15,000 case studies conducted over a decade and are now being scaled and commercialized through a platform that will leverage key exponential technologies to revolutionize personalized healthcare. It is GNQ's belief that the successful deployment of its genomics-driven generative AI in silico clinical trials platform powered by quantum computing has the potential to provide the following benefits to drug development:
GNQ 由 My Next Health Inc. 於 2023 年 8 月成立。(”MNH“),一家在特拉華州註冊成立的醫療保健公司,其願景是通過部署基於基因組學的人工智能和量子平台進行臨床試驗和護理點解決方案,改善全球醫療保健行業。MNH的平台使用有關基因系統如何相互作用以及與表觀遺傳因子相互作用的專有見解來推動關鍵代謝途徑。這些見解基於十年來進行的15,000多個案例研究,目前正在通過一個平台進行擴展和商業化,該平台將利用關鍵指數技術徹底改變個性化醫療保健。GNQ認爲,成功部署其由量子計算提供支持的基因組學驅動的生成式人工智能模擬臨床試驗平台有可能爲藥物開發帶來以下好處:
Rapid Drug Development: In silico clinical trials enable us to expedite the drug development process by simulating and predicting drug responses, significantly reducing the time required for clinical trials and the overall cost of the trials.
快速藥物開發: 模擬臨床試驗使我們能夠通過模擬和預測藥物反應來加快藥物研發過程,從而顯著減少臨床試驗所需的時間和試驗的總體成本。
Improved Safety and Efficacy: In silico clinical trials enhance our understanding of drug mechanisms, allowing for the prediction of adverse effects and optimization of drug dosages, thereby increasing safety and efficacy.
提高安全性和有效性: 模擬臨床試驗增強了我們對藥物機制的理解,允許預測不良反應和優化藥物劑量,從而提高安全性和有效性。
Personalized Medicine: Our generative AI platform simulates the effects of drugs across diverse profiles of human digital twins (digital replicas of real people), enabling the development of targeted therapies and facilitating personalized medicine across disparate and diverse populations.
個性化醫學: 我們的生成式人工智能平台模擬藥物對人類數字雙胞胎(真實人物的數字副本)的不同特徵的影響,從而能夠開發靶向療法,促進針對不同人群的個性化醫療。
Equitable Representation: Our drug simulation process is inherently designed to include genetic, epigenetic and lifestyle variances based on ethnic and minority populations, thereby ensuring equitable representation of underserved minorities in the drug development process.
公平代表性:我們的藥物模擬過程本質上旨在包括基於族裔和少數群體群體的遺傳、表觀遺傳學和生活方式差異,從而確保在藥物研發過程中獲得的服務不足的少數群體的公平代表性。
MNH has exclusive and perpetual global rights to the use of certain technology that relates to functional genomics as well as the supporting clinical data, programs, methods, and interpretation know-how and analytics for use in a number of commercial applications. For more information on GNQ, see its website at .
MNH擁有使用與功能基因組學相關的某些技術以及用於多種商業應用的支持性臨床數據、項目、方法、解釋知識和分析的獨家和永久的全球權利。有關 GNQ 的更多信息,請訪問其網站。
Option Agreement
期權協議
The Company entered into an Option Agreement with GNQ, dated November 30, 2023, as amended (the "Option Agreement") pursuant to which GNQ granted the Company the right and option (the "Option") to purchase up to 50% of the common shares in the capital of GNQ (each, a "GNQ Share") during the period (the "Option Period") commencing on November 30, 2023 and ending on the earlier of November 30, 2026 or the date of a specified liquidity event involving GNQ (as set out in the Option Agreement). Pursuant to the Option Agreement, the Company agreed to acquire an initial 20% of the post-investment fully diluted GNQ Shares for consideration consisting of $2,500,000 and the issuance of 7,500,000 common shares in the capital of the Company (each, a "Trenchant Share") to GNQ (collectively, the "Initial Investment"). To date, the Company has invested $700,000 of the Initial Investment in exchange for 59,322 GNQ Shares being 5.6% of total issued and outstanding GNQ Shares on a fully diluted basis.
該公司於2023年11月30日與GNQ簽訂了期權協議,該協議經修正(”期權協議“) 據此,GNQ授予了公司權利和期權(”選項“)購買GNQ資本中高達50%的普通股(每股一股”GNQ 分享“)在此期間(”期權期“)從2023年11月30日開始,到2026年11月30日或涉及GNQ的特定流動性事件發生之日(如期權協議所規定)以較早者爲準。根據期權協議,公司同意收購投資後全面攤薄後的GNQ股票的初始20%,包括250萬美元和發行公司資本中的750萬股普通股(每股均爲”Trenchant Share“) 到 GNQ(統稱爲”初始投資“)。迄今爲止,公司已投資了70萬美元的初始投資,以換取59,322股GNQ股票,按全面攤薄計算,佔已發行和流通GNQ股票總額的5.6%。
Effective March 5, 2024, the Company has agreed with GNQ that, on or prior to March 15, 2024, the Company will make a $500,000 cash payment in exchange for 52,966 GNQ Shares and that, on or prior to April 12, 2024, the Company will make a $1,300,000 cash payment and issue 7,500,000 Trenchant Shares in exchange for such number of GNQ Shares which would result in the Company owning an aggregate of 20% of the total issued and outstanding GNQ Shares on a fully-diluted basis, when combined with the GNQ Shares previously held by the Company, as at the date of the completion of the issuance of the GNQ Shares.
自2024年3月5日起,公司已與GNQ達成協議,在2024年3月15日當天或之前,公司將支付50萬美元的現金以換取52,966股GNQ股票;在2024年4月12日當天或之前,公司將支付13萬美元現金併發行7,500,000股Trenchant股票,以換取如此數量的GNQ股份,這將使公司共擁有20%的股份截至公司當日已發行和流通的GNQ股票總額,經全面攤薄後的GNQ股票與公司先前持有的GNQ股份合計完成GNQ股票的發行。
ON BEHALF OF THE BOARD
代表董事會
TRENCHANT CAPITAL CORP.
TRENCHANT CAPITAL CORP
Per: "Eric Boehnke"
每個: “Eric Boehnke”
Eric Boehnke, CEO
首席執行官埃裏克·博恩克
For further information, please contact:
欲了解更多信息,請聯繫:
Trenchant Capital Corp.
Eric Boehnke, CEO
Phone: (604) 307-4274
Trenchant 資本公司
首席執行官埃裏克·博恩克
電話:(604) 307-4274
TRENCHANT CAPITAL CORP.
TRENCHANT CAPITAL CORP
Certain statements in this press release are forward-looking statements, which reflect the expectations of management regarding the Company's completion of the Initial Investment and related transactions. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, statements regarding MNH's and GNQ's business and potential in the industries in which they operate, the Company completing the transactions as described herein or at all, and the obligations to be satisfied under the Amended Option Agreement. Such statements are subject to risks and uncertainties that may cause actual results, performance, or developments to differ materially from those contained in the statements, including risks related to factors beyond the control of the Company. The risks include that the business of MNH and GNQ may not be feasible or continue as planned, as well as other risks that are customary to transactions of this nature. Further, inflationary pressures, rising interest rates, the global financial climate and the ongoing conflicts in Ukraine and the Middle East and surrounding regions are some additional factors that are affecting current economic conditions and increasing economic uncertainty, which may impact the operating performance, financial position, and future prospects of the Company, MNH, GNQ, and the transaction as a whole. Collectively, the potential impacts of this economic environment pose risks that are currently indescribable and immeasurable. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
本新聞稿中的某些陳述是前瞻性陳述,反映了管理層對公司完成初始投資和相關交易的預期。前瞻性陳述由不純歷史的陳述組成,包括任何有關未來信念、計劃、預期或意圖的陳述,包括但不限於有關MNH和GNQ在其經營行業中的業務和潛力、公司按本文所述完成交易或完全按照修訂後的期權協議應履行的義務的陳述。此類陳述存在風險和不確定性,可能導致實際業績、業績或發展與聲明中包含的結果存在重大差異,包括與公司無法控制的因素相關的風險。風險包括MNH和GNQ的業務可能不可行或無法按計劃繼續,以及此類性質交易所慣用的其他風險。此外,通貨膨脹壓力、利率上升、全球金融環境以及烏克蘭和中東及周邊地區持續的衝突是影響當前經濟狀況和增加經濟不確定性的其他因素,可能會影響公司、MNH、GNQ和整個交易的經營業績、財務狀況和未來前景。總的來說,這種經濟環境的潛在影響構成了目前難以描述和無法估量的風險。無法保證前瞻性陳述所預期的任何事件都會發生,也無法保證如果發生的話,公司將從中獲得什麼好處。除非法律要求,否則公司不打算或義務更新或修改任何前瞻性陳述,無論是由於新信息、未來事件還是其他原因。
Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
加拿大證券交易所和市場監管機構(該術語在加拿大證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
譯文內容由第三人軟體翻譯。